Cervos Medical

What Cervos Medical does

Cervos Medical LLC is a privately held medical device company headquartered at 30 Doherty Ave, Avon, Massachusetts, operating as a wholly-owned subsidiary of Ranfac Medical. Founded in 2021 and operating with a lean team of 1-10 employees, the company develops a portfolio of autologous orthobiologic devices designed to harness the body's natural regenerative mechanisms for musculoskeletal applications, including bone repair, joint preservation, and chronic pain management.

The product lineup spans seven branded devices: Marrow Cellution (centrifuge-free bone marrow aspiration in approximately 2 minutes from a single access site), KeyPRP (a proprietary concave-surface platelet concentration system achieving the 10 billion platelet benchmark with up to 30x concentration over baseline), VelvetDBF (demineralized bone fiber allograft with verified osteoinductive potential), PercuGraft (minimally invasive autologous cancellous bone dowel harvester), IO Access (intraosseous delivery cannulas with K-wire drill enablement), Lipo-Pro (centrifuge-based adipose tissue processing isolating progenitor cells and stromal vascular fraction), and HydraCell (a combined BMA-plus-DBF kit for integrated bone grafting). All devices are FDA-cleared and manufactured in US-based ISO-9000 registered facilities with validated terminal sterilization, supported by 17+ (and as many as 23) peer-reviewed publications covering over 1,000 patients across knee, hip, shoulder, spine, and sports medicine indications.

Cervos generates revenue through hardware sales of single-use disposables and reusable devices to healthcare facilities, distributed via direct enterprise field sales to orthopedic surgeons, sports medicine physicians, and regenerative medicine practitioners, alongside a dedicated distributor portal for channel partners globally. The company employs a content- and education-led go-to-market motion, leveraging a clinical resource library, education portal, and physician testimonials to drive adoption among specialty clinical buyers. No pricing is publicly disclosed; transactions are quote-based and routed through direct sales engagement or distributor resellers.

Name

Cervos Medical

Legal name

Cervos Medical LLC

Website

https://cervos.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Cervos Medical is a privately held medical device company (subsidiary of Ranfac Medical) that develops and sells autologous orthobiologic devices — including bone marrow aspiration, PRP concentration, and demineralized bone fiber systems — to orthopedic surgeons, sports medicine physicians, and hospitals performing regenerative musculoskeletal procedures.

Ownership category

akta.pro rank

Product category

Orthobiologic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Orthobiologic medical devices
• Bone marrow aspiration
• Platelet-rich plasma systems
• Regenerative medicine devices
• Demineralized bone fiber

Headquarters

HQ city

Marshfield

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of orthobiologic medical devices including bone marrow aspiration devices, PRP concentration systems, demineralized bone fiber allografts, intraosseous cannulas, and adipose tissue processing systems. Products are sold as single-use disposables and reusable devices to healthcare facilities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Cervos Medical develops, manufactures, and sells FDA-cleared autologous orthobiologic medical devices that harness the body's natural regenerative mechanisms for orthopedic surgeons, sports medicine physicians, and regenerative medicine practitioners. The portfolio spans centrifuge-free bone marrow aspiration devices, high-dose customizable platelet-rich plasma systems, demineralized bone fiber allografts, minimally invasive bone grafting harvesters, intraosseous delivery cannulas, adipose tissue processors, and combined procedural hydration kits sold as single-use disposables and reusable instruments to hospitals, surgical centers, and specialty clinics.

Product overview

Cervos Medical develops a portfolio of best-in-class orthobiologic medical devices for autologous regenerative medicine. The product lineup includes Marrow Cellution (centrifuge-free bone marrow aspiration), KeyPRP (high-dose customizable platelet-rich plasma), VelvetDBF (demineralized bone fiber allograft), PercuGraft (minimally invasive bone dowel harvester), HydraCell (combines bone marrow aspiration with demineralized bone fiber), IO Access (intraosseous delivery cannulas), and Lipo-Pro (adipose tissue processing). These devices are designed to harness the body's natural reparative mechanisms for musculoskeletal conditions, with a focus on bone repair, joint preservation, and chronic pain management.

Differentiator

Problem solved

Functional benefit

Brands

• Marrow Cellution™: Bone Marrow Aspiration Device - The only centrifuge-free BMA system yielding highly concentrated bone marrow aspirate in just 2 minutes from a single access site.
• KeyPRP™
• VelvetDBF™
• PercuGraft™
• IO Access™
• Lipo-Pro™
• HydraCell™

Products and services

• Marrow Cellution™ FDA-cleared bone marrow aspiration device that uses a closed distal tip with precision side ports to block peripheral blood dilution and capture higher cell counts from undisturbed cancellous bone, delivering highly concentrated bone marrow aspirate in approximately 2 minutes from a single access site without centrifugation. It is sold to orthopedic surgeons, sports medicine physicians, and regenerative medicine practitioners performing autologous orthobiologic procedures in hospitals, surgical centers, and specialty clinics.
• KeyPRP™ FDA-cleared platelet-rich plasma concentration system that uses a proprietary concave collection surface to consistently hit the 10 billion platelet benchmark with up to 30x concentration over baseline and a customizable final composition with volume reduction to as low as 1.5 cc. It is sold to sports medicine, regenerative medicine physicians, and orthopedic practices for point-of-care PRP delivery.
• VelvetDBF™ 100% allograft cortical demineralized bone fiber product with elongated, interlocking fibers that create an osteoconductive scaffold and verified osteoinductive potential confirmed by ALP activity, BMP-2/BMP-7 expression, and in vivo OI scoring. It rehydrates rapidly with blood, bone marrow aspirate, PRP, or saline and is sold to orthopedic surgeons and hospitals for bone grafting, trauma repair, joint reconstruction, and spine fusion supplementation.
• PercuGraft™ Minimally invasive autologous cancellous bone dowel harvester with swaged introducer, harvesting spoon, sounding rod, and screw mechanism that uses controlled mechanical advantage to capture intact cancellous bone containing native bone-forming cells, progenitor cells, and a dense vascular network. It is sold to orthopedic surgeons and surgical centers for precision percutaneous bone grafting with reduced patient morbidity.
• IO Access™ Intraosseous delivery cannulas available in multiple gauges and lengths with open or closed-tip options, K-wire drill enablement, auto-locking keyway, and laser-etched depth markings for precise intraosseous biologic delivery. They are sold to orthopedic surgeons, sports medicine physicians, and other specialists for intraosseous access and biologic administration across clinical applications and anatomical locations.
• Lipo-Pro™ High-density adipose grafting system that uses a centrifuge-based process with an internal filter to gently micronize fat, isolating progenitor cells and stromal vascular fraction for regenerative applications. It is sold to plastic surgeons, orthopedic surgeons, and regenerative medicine practitioners for streamlined adipose harvest and preparation.
• HydraCell™ Combined cellular hydration system that pairs Marrow Cellution bone marrow aspirate with VelvetDBF demineralized bone fiber in a single centrifuge-free kit for an approximately 2-minute Aspirate-to-Application workflow. It is sold to orthopedic surgeons and hospitals as a unified bone grafting kit that streamlines procurement and OR inventory.

Quantifiable outcome

• CFU-f counts of 5,010 per mL and TNC density of 50.5 million per mL with Marrow Cellution, comparable to cancellous bone autograft gold standard (4,564 CFU-f/mL; 55.7M TNC/mL)
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Ranfac MedicalcoreOthersRanfac Medical is the parent company of Cervos Medical. As a wholly-owned subsidiary, Cervos leverages Ranfac's 130+ years of specialized medical device manufacturing capabilities, including ISO-9000 registered facilities and established distribution networks.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Isto Biologics: Isto Biologics manufactures bone graft substitutes and orthobiologic products including demineralized bone matrix allografts that compete directly with VelvetDBF. The company serves the same orthopedic and spine surgeon customer base for bone grafting and fusion procedures.
• MTF Biologics: MTF Biologics is one of the largest tissue banks and orthobiologic allograft suppliers, offering demineralized bone fiber and putty products, sports medicine allografts, and other regenerative medicine tissues that compete with Cervos's VelvetDBF and other allograft offerings across orthopedic and spine applications.
• EmCyte (a Globus Medical company): EmCyte (acquired by Globus Medical) manufactures centrifuge-based PRP and bone marrow concentration systems, directly competing with KeyPRP and Marrow Cellution. Now operating within Globus Medical's orthopedic spine and biologics franchise, EmCyte has significantly expanded commercial reach and competes for the same regenerative medicine physician customers.
• Terumo BCT: Terumo BCT (through its bone marrow processing product line) develops cell concentration systems including the SmartPReP platform historically used in BMAC procedures. It competes directly with Marrow Cellution in the bone marrow aspiration and concentration category across hospital and surgical center settings.
• Arthrex: Arthrex is the dominant orthopedic sports medicine device company and offers competing PRP preparation systems and bone marrow concentration products used by the same orthopedic surgeon customer base as Cervos. Its Angel System for PRP and ACP kits compete directly with KeyPRP, and Arthrex's vast sales force and bundled procedural sets represent the primary competitive threat in orthobiologics.

Broad incumbents

• Zimmer Biomet: Zimmer Biomet is a global orthopedic device leader offering PRP and bone marrow concentration solutions within its broader sports medicine and biologics portfolio. While orthobiologics is not its primary focus, the company's massive sales infrastructure and hospital relationships make it a significant competitive force across all regenerative medicine categories Cervos serves.
• Stryker: Stryker's Orthopaedics and Spine divisions offer regenerative medicine and bone graft substitute products that compete with the Cervos portfolio in joint preservation and spine fusion applications. As one of the largest orthopedic device companies globally, Stryker competes primarily through scale, bundled contracts, and established hospital partnerships.

Emerging players

• Regenexx: Regenexx is a regenerative medicine practice network and laboratory service that uses bone marrow concentrate and PRP procedures, representing both a potential customer channel for Cervos devices and a competing clinical offering in the same interventional orthopedics space.
• Vivex Biologics: Vivex Biologics develops amniotic and tissue-based orthobiologic products for orthopedic, spine, and sports medicine applications. It competes with Cervos's allograft portfolio (particularly VelvetDBF) and targets overlapping regenerative medicine physician and hospital customers.
• Royal Biologics: Royal Biologics is a regenerative medicine company offering amniotic membrane products, orthobiologics, and surgical solutions that overlap with Cervos's orthopedic and sports medicine focus. As a smaller specialty player, it competes in similar surgeon accounts for orthobiologic procedural spend.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/cervos-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cervos Medical